新辅助白蛋白结合型紫杉醇对比紫杉醇后序贯蒽环类方案治疗ERBB2/HER2阴性乳腺癌的随机III期ETNA试验
ETNA试验纳入695例中心确认的ERBB2/HER2阴性早期或局部晚期乳腺癌患者,随机接受白蛋白结合型紫杉醇(125 mg/m2)或紫杉醇(90 mg/m2)周疗4周期后序贯4周期蒽环类方案。主要终点pCR率在两组间无统计学显著差异(22.5% vs 18.6%;OR 0.77;95%CI 0.52-1.13;白蛋白结合型紫杉醇组严重不良事件及≥3级周围神经病变发生率更高。
要点
- 白蛋白结合型紫杉醇组严重不良事件(16.0% vs 11.3%)及≥3级周围神经病变(4.5% vs 1.8%)更多。
- 肿瘤亚型(三阴性 vs 管腔B样)是影响治疗结局的最显著因素(OR 4.85;95%CI 3.28-7.18)。
核心结论
- 白蛋白结合型紫杉醇对比紫杉醇在新辅助化疗中提高pCR率未达统计学显著。
- 多因素分析显示肿瘤亚型是影响治疗结局的最显著因素(OR 4.85;95%CI 3.28-7.18)。
研究设计与样本
- 多中心、开放标签、随机III期试验,由GEICAM与BCRC-WA合作开展。
- 814例注册,695例中心确认合格并随机分配至紫杉醇90 mg/m2组(349例)或白蛋白结合型紫杉醇125 mg/m2组(346例)。
- 两药均于第1、2、3周给药后休息1周,共4周期,随后按研究者选择接受4周期蒽环类方案。
- 主要终点为手术时乳腺及腋窝淋巴结无浸润细胞(ypT0/is ypN0)的pCR率;次要终点为耐受性与安全性。
主要发现
- 紫杉醇组335例中38例(11.3%)发生至少1次严重不良事件,白蛋白结合型紫杉醇组337例中54例(16.0%)。
- ≥3级周围神经病变在紫杉醇组335例中发生6例(1.8%),白蛋白结合型紫杉醇组337例中发生15例(4.5%)。
关键数值与推荐
- pCR定义为手术时乳腺及腋窝淋巴结无浸润细胞(ypT0/is ypN0)。
- 紫杉醇剂量90 mg/m2,白蛋白结合型紫杉醇剂量125 mg/m2,均为每周第1、2、3周给药后休息1周,共4周期。
临床怎么用
- 在ERBB2/HER2阴性乳腺癌新辅助化疗中,白蛋白结合型紫杉醇未显示较紫杉醇显著提高pCR率。
- 选择含白蛋白结合型紫杉醇方案时需权衡更高的严重不良事件及≥3级周围神经病变风险。
局限性
- 原文摘要未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did not reduce activity. Nab-paclitaxel is an albumin-bound nanoparticle of paclitaxel that allows for safe infusion without premedication, and its use led to a significantly higher rate of pCR in the GeparSepto trial. OBJECTIVE: To determine whether nab-paclitaxel improves the outcomes of early and locally advanced human epidermal growth factor receptor 2 (ERBB2/HER2)-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, open-label study, in collaboration with Grupo Español de Investigación en Cáncer de Mama (GEICAM) and Breast Cancer Research Center-Western Australia (BCRC-WA), patients with newly diagnosed and centrally confirmed ERBB2/HER2-negative breast cancer were recruited. Participants were randomly allocated to paclitaxel, 90 mg/m2 (349 patients), or nab-paclitaxel, 125 mg/m2 (346 patients). The 2 drugs were given on weeks 1, 2, and 3 followed by 1 week of rest for 4 cycles before 4 cycles of an anthracycline regimen per investigator choice. MAIN OUTCOMES AND MEASURES: The primary end point was the rate of pCR, defined as absence of invasive cells in the breast and axillary nodes (ie, ypT0/is ypN0) at the time of surgery. A secondary end point was to assess tolerability and safety of the 2 regimens. RESULTS: From May 2013 to March 2015, 814 patients were registered to the study; 695 patients met central confirmation eligibility and were randomly allocated to receive either paclitaxel (349), or nab-paclitaxel (346) (median age, 50 years; range, 25-79 years). The intention-to-treat analysis of the primary end point pCR revealed that the improved pCR rate after nab-paclitaxel (22.5%) was not statistically significant compared with paclitaxel (18.6%; odds ratio [OR], 0.77; 95% CI, 0.52-1.13; P = .19). Overall, 38 of 335 patients (11.3%) 11.3% of patients had at least 1 serious adverse event in the paclitaxel arm and 54 of 337 patient (16.0%) in the nab-paclitaxel arm. Peripheral neuropathy of grade 3 or higher occurred in 6 of 335 patients (1.8%) and in 15 of 337 (4.5%), respectively. CONCLUSIONS AND RELEVANCE: The improved rate of pCR after nab-paclitaxel was not statistically significant. The multivariate analysis revealed that tumor subtype (triple-negative vs luminal B-like) was the most significant factor (OR, 4.85; 95% CI, 3.28-7.18) influencing treatment outcome. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01822314.
引用
- Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol. 2018. PMID: 29327055. doi:10.1001/jamaoncol.2017.4612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。